yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Top Links You Must Click On

Sets up US subsidiary

YORK, UK -- (Marketwire) -- 11/26/12 --

          Tissue Regenix sets up United States subsidiary
           to target growing regenerative medicine market

Tissue Regenix appoints Greg Bila President, Tissue Regenix USA

YORK, 26 November 2012. Tissue Regenix Group plc ('Tissue Regenix') has
set up a subsidiary company in the United States, as part of its
commercialisation strategy for its dCELL® technology platform.

Tissue Regenix is also pleased to announce the recruitment of Greg Bila
from Kinetic Concepts Inc. ('KCI') as President of Tissue Regenix USA.
Greg's recent career at KCI has spanned a number of sales & marketing
roles and brings over 20 years' experience in pharmaceutical and
medical device fields.

Tissue Regenix will use its patented dCELL® technology to target a
number of areas. Work will focus initially on applying the dCELL® to
the treat a number of chronic diseases but, over time, could be
developed for other applications including vascular repair, heart valve
replacement and knee repair. Tissue Regenix's dCELL® technology have
delivered encouraging interim data.

Antony Odell, Managing Director of Tissue Regenix commented: "This is a
significant step in the development of Tissue Regenix. It is an
excellent signal of the strength of TR's proposition that we can
attract people of Greg's calibre and experience, we look forward to
advancing our plans in the US with him at the helm. The United States
presents an opportunity to establish our platform dCELL® technology in
a market potentially worth hundreds of millions of dollars."

Greg Bila, President of Tissue Regenix Wound Care Inc. said: "I am
excited to be able to join Tissue Regenix at the beginning of its
expansion into the United States. TR's dCELL® technology will be a
welcome offering for the treatment of number of diseases and the
potential indications are attractive."

The potential advantages of the Company's dCELL technology over other
types of decellularised tissue scaffolds was underpinned at Tissue
Regenix technology day in October by Dr Alan Dardik, Associate
Professor of Surgery at Yale University, who has conducted pre-clinical
studies of Tissue Regenix dCELL® vascular patch and published the
results in the scientific journal PLoS ONE.

Speaking about those studies Dr Dardik commented: "I have to say my
impression is it's the closest thing on the market to a tissue
engineered patch. It's the next technology. Other companies are trying
to attract stem-cells but they've already got the stem cells that are
coming into their patch."


For Further Information

Tissue Regenix Group plc:         01904 435 176
Antony Odell

Newgate Communications:
Alistair Kellie                   07801 234598
Andrew Adie                       07970 256512
Martin Greig                      07584 221513

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. The company's patented decellularisation
('dCELL®) technology removes DNA and other cellular material from
animal and human tissue leaving an acellular tissue scaffold which is
not rejected by the patient's body which can then be used to repair
diseased or worn out body parts. The potential applications of this
process are diverse and address many critical clinical needs such as
vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Enterprise Open Source Magazine Latest Stories . . .
Apache Hadoop is a key technology for gaining business insights from your Big Data, but the penetration into enterprises is shockingly low. In fact, Apache Hadoop and Big Data proponents recognize that this technology has not yet achieved its game-changing business potential. In his ...
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys Servic...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the n...
Ten short years ago, Apache Hadoop was just a small project deployed on a few machines at Yahoo and within a few years, it had truly become the backbone of Yahoo’s data infrastructure. Additionally, the current Apache Hadoop market is forecasted to surpass $16 billion by 2020. This mi...
The Open Connectivity Foundation (OCF), sponsor of the IoTivity open source project, and AllSeen Alliance, which provides the AllJoyn® open source IoT framework, today announced that the two organizations’ boards have approved a merger under the OCF name and bylaws. This merger will ad...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers